Please type a plus sign (+) inside this box	4	ł
---	---	---

ATENT

Pleas	se type a plus sign (+) inside this box [+]	Attorney Docket P1942H1 PA
EV 3	51928472 US: Express Mail Number	July 25, 2003: Date of Deposit
	IN THE UNITED STATES PATENT	AND TRADEMARK OFFICE
Comm P.O. B	top PATENT APPLICATION issioner for Patents ox 1450 Idria, VA 22313-1450	
	NON-PROVISIONAL APPLICATION TRA	NSMITTAL UNDER 37 CFR 1.53(b)
Transn	nitted herewith for filing is a non-provisional paten	it application:
Invento	or(s) (or Application "Identifier"):	
	Anan Chuntharapai, Colma, CA Iqbal Grewal, Fremont CA Kyung Jin Kim, Cupertino CA Minhong Yan, Burlingame, CA	
Title:	TACI Antibodies and Uses Thereof	
1.	Type of Application	
[]	This application is for an original, non-provisional	al application.
[X]	This is a non-provisional application claiming 60/398,530 , filedJuly 25, 2002 , the entire by reference.	
[]	This is a [] continuation-in-part [] continuation-in-part [] continuation priority to application Serial Number, filed _ incorporated by reference.	ation [] divisional application claiming , the entire disclosure of which is hereby
2.	Papers Enclosed Which Are Required For Fil (Non-provisional) 93 pages of specification 5 pages of claims 1 page of abstract 16 sheets of drawings [] formal [X] informal	ling Date Under 37 CFR 1.53(b)

3. **Declaration or Oath**

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

X An executed declaration of the inventor(s) [] is enclosed [X] will follow.

P1942R1

		(for Cont./Div. where inventorship is the same or inventor(s) being deleted) A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).
		(for Cont./Div. where inventor(s) being deleted) A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).
4.	Assiç	gnment
	X_	(for new and CIP applications) An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [X] will follow.
		(for cont./div.) The prior application is assigned of record to Genentech, Inc.
5.	Amer	ndments (for continuation and divisional applications)
		Cancel in this application original claims _ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
		A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

P1942R1 Page 3 of 4

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION						
Number Filed		Numbe	er Extra	Rate	Basic Fee 37 CFR 1.16(a)	
					\$750.00	
Total Claims	62	- 20 =	42	X \$18.00	\$756.00	
Independent Claims	23	- 3=	20	X \$84.00 \$1,6		
Multiple dependent claim(s), if any				+ \$280.00	\$280.00	
Filing Fee Calculation					\$3,466.00	

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$3,466.00. A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. <u>A duplicate copy of this transmittal is enclosed</u>.

9. Additional Papers Enclosed

- [] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- [] A new Power of Attorney or authorization of agent.
- [X] Other: Application Data Sheet

10.	Maintenance	of	Copendency	of	Prior	Application	(for	continuation	and	divisional
applica	ations)									

[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

	A petition, fee and/or response has been filed to extend the term in
	the pending prior application until
	A copy of the petition for extension of time in the <i>prior</i> application is attached.

P1942R1 Page 4 of 4

11. Correspond nce Address:

<u>X</u> Address all future communications to:

Attn: Elinor K. Shin

Respectfully submitted, GENENTECH, INC.

Date: July 25, 2003

Elinor K. Shin

Reg. No. 43,117 Telephone No. (650) 225-3536

PATENT TRADEMARK OFFICE #138589